OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism
Lena Ripa, Jenny Sandmark, Glyn A. Hughes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14188-14207
Closed Access | Times Cited: 15

Showing 15 citing articles:

Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases
Kairui Yue, Simin Sun, Zequn Yin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1

Hydrazides as Inhibitors of Histone Deacetylases
María do Carmo Carreiras, José Marco‐Contelles
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13512-13533
Closed Access | Times Cited: 5

Quantum chemical package Jaguar: A survey of recent developments and unique features
Yixiang Cao, Ty Balduf, Michael D. Beachy, et al.
The Journal of Chemical Physics (2024) Vol. 161, Iss. 5
Closed Access | Times Cited: 5

Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies
Ziqian Huang, Ling Li, Binbin Cheng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117218-117218
Open Access | Times Cited: 4

Design, synthesis, and biological evaluation of novel artemisinin-based HDAC inhibitors with antitumor and antimalarial activities
Jin He, Youyou He, Yunan Qian, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108312-108312
Closed Access

Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6
Edoardo Cellupica, Aureliano Gaiassi, Ilaria Rocchio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5885-5885
Open Access | Times Cited: 3

Synthesis and Antitumor Activity Evaluation of Novel Echinatin Derivatives with a 1,3,4-Oxadiazole Moiety
Xing Tian, Zihan Sun, Ye Zhong, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2254-2254
Open Access | Times Cited: 2

2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?
Beate König, Finn K. Hansen
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 899-903
Open Access | Times Cited: 2

Tackling Triple Negative Breast Cancer with HDAC inhibitors: 6 is the isoform!
A Guadagni, Simona Barone, Antonella Ilenia Alfano, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116884-116884
Open Access | Times Cited: 2

Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer
Zuoyang Wang, Zhichao Shi, Shiqi Yang, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1516-1525
Closed Access | Times Cited: 1

Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Yasir S. Raouf, Carlos Moreno–Yruela
JACS Au (2024) Vol. 4, Iss. 11, pp. 4148-4161
Open Access | Times Cited: 1

Design, synthesis, and histone deacetylase inhibition study of novel 4‐(2‐aminoethyl) phenol derivatives
Runesh Podili, KM Abha Mishra, Ashish Sunil Akkewar, et al.
Journal of Biochemical and Molecular Toxicology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 2

Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders
Jonathan van Eyll, Robert Prior, Sylvain Célanire, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 9, pp. 719-737
Closed Access

Page 1

Scroll to top